---
title: "Lixte Biotechnology Holdings, Inc. (LIXT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LIXT.US.md"
symbol: "LIXT.US"
name: "Lixte Biotechnology Holdings, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T21:39:07.322Z"
locales:
  - [en](https://longbridge.com/en/quote/LIXT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LIXT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LIXT.US.md)
---

# Lixte Biotechnology Holdings, Inc. (LIXT.US)

## Company Overview

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company’s LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [lixte.com](https://lixte.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.90 | 434 | - | - | - |
| PB | 8.19 | 375 | 30.39 | 10.81 | 8.52 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LIXT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LIXT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LIXT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LIXT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**